Senaparib Medicine 04 December 2025 Extended indication Maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer. Therapeutic value Possible equal value Total cost € 18,700,000.00 Registration phase Registration application pending Product Active substance Senaparib Domain Oncology Reason of inclusion New medicine (specialité) Main indication Ovarian cancer Extended indication Maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer IMPACT Portfolio holder Mechanism of action PARP inhibitor Route of administration Therapeutical formulation Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date August 2025 Expected Registration September 2026 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Andere PARP-remmers Therapeutic value Possible equal value This assessment does not indicate any potential inclusion in the package. Substantiation De eerste studie is positief op progression-free survival (PFS). Er is nog geen overall survival (OS) data. Mogelijk zal het vergelijkbaar zijn ten opzichte van andere PARP-remmers. Duration of treatment Frequency of administration 1 times a day Dosage per administration 100 mg References NCT04169997 (FLAMES) Additional remarks Expected patient volume per year Patient volume 374 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References 1: IKNL2022; Additional remarks In 2022 waren er volgens IKNL 374 diagnoses van epitheliaal ovariumcarcinoom stadium IV (1). Expected cost per patient per year Cost € < 50,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks Op basis van vergelijkbare PARP-remmers Potential total cost per year Total cost € 18,700,000.00 Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks